ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Two mechanisms known to be involved in inflammation are the production of nitric oxide by the enzyme inducible nitric oxide synthase (iNOS) and the formation of prostaglandins by cyclooxygenase-2 (COX-2). COX-2 inhibitors are used as anti-inflammatory agents, but they have come under fire recently. Solomon H. Snyder, Sangwon F. Kim, and Daniel A. Huri at Johns Hopkins University School of Medicine now show that iNOS binds to COX-2 and S-nitrosylates it on one of its cysteine residues, increasing the catalytic activity of COX-2 (Science 2005, 310, 1966). Disrupting the interaction between the two enzymes prevents NO-mediated activation of COX-2. The authors suggest that preventing this interaction is a possible therapeutic avenue that would be synergistic with COX-2 inhibitors, allowing smaller doses to be used.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter